Equatorial Guinea vs Rwanda: Average cost of drugs for extensively drug-resistant tuberculosis
Equatorial Guinea
1,500 constant 2022 US$
in 2024
Rwanda
1,483 constant 2022 US$
in 2024
Equatorial Guinea rank
33rd
Rwanda rank
35th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Equatorial Guinea
- Rwanda
How they compare
Equatorial Guinea currently reports 1,500 constant 2022 US$ against 1,483 constant 2022 US$ in Rwanda, a difference of 17 constant 2022 US$.
The two have swapped places 1 time across 6 shared years of data; in 2019 it was Rwanda ahead.
Equatorial Guinea ranks 33rd and Rwanda ranks 35th of 56 countries.
Rwanda has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Equatorial Guinea | Rwanda | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4,000 constant 2022 US$ | 4,286 constant 2022 US$ | 286 constant 2022 US$ | Rwanda |
| 2020s | 2,301 constant 2022 US$ | 3,070 constant 2022 US$ | 768.8 constant 2022 US$ | Rwanda |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Equatorial Guinea or Rwanda?
- Equatorial Guinea, at 1,500 constant 2022 US$ against 1,483 constant 2022 US$ in Rwanda as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Equatorial Guinea and Rwanda?
- 17 constant 2022 US$, with Equatorial Guinea ahead.
- How many years of comparable data are there for Equatorial Guinea and Rwanda?
- 6 years are reported by both, from 2019 to 2024.
- How do Equatorial Guinea and Rwanda rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Equatorial Guinea ranks 33rd and Rwanda ranks 35th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.